Kailos Genetics has become a wholly-owned subsidiary of healthŌme, which can now leverage Kailos Genetics’ expertise to expand its testing capabilities, and become an integrated precision health management company
US-based genomics company healthŌme has acquired Kailos Genetics, a CLIA-certified and CAP-accredited genetic testing laboratory and supplier of reagents for next-generation sequencing (NGS).
Both companies are based at the HudsonAlpha Institute for Biotechnology, a non-profit research institute in Huntsville, Alabama, US.
With the acquisition, Kailos Genetics became a wholly-owned subsidiary of healthŌme, and continues to provide its services and reagents to the marketplace.
HealthŌme is currently providing its hereditary cancer risk screening and pharmacogenetic testing through Kailos Genetics.
The company can now leverage Kailos Genetics’ expertise to expand its testing capabilities and become an integrated precision health management company.
Kailos Genetics is enabled to diversify its laboratory services business model beyond traditional healthcare reimbursement and payer systems.
In addition, the company can widen market reach for its testing services, unlock new growth opportunities, and lay the foundation for its future success.
HealthŌme CEO Darren Rowe said: “Our merger with Kailos Genetics builds upon the partnership we began with Kailos when healthŌme was founded and is rooted in our shared vision and values.
“This merger creates an optimal path to improve health, enhance long-term company value, and provides opportunities to cultivate market-leading solutions for the life insurance industry.
“We wholeheartedly welcome the exceptionally talented Kailos team to the healthŌme family. Together, we are poised to make a profound impact on improving and extending healthy life through the alternative funding channels of life and critical illness insurance.”
According to healthŌme, the acquisition of Kailos Genetics provides access to advanced technology and research, including its advanced CLIA-certified and CAP-accredited laboratory facilities, patented and licensed technology, and robust research capabilities.
The business combination is said to expand the service portfolio and enable the development of a broader range of clinical testing options.
The integrated offering provides individuals, physicians, hospitals, and healthcare providers, along with healthŌme’s life insurance clients, with access to advanced testing solutions.
In addition, the acquisition brings together a diverse group of experts in the field of genomics, clinical diagnostics development, and clinical laboratory management.
Kailos Genetics founder and CEO Brian Pollock said: “Kailos is excited to become part of the healthŌme family, bringing our expertise in sequencing-based solutions to deliver unparalleled value to healthŌme clients while upholding the exceptional service our existing customers expect.”